147 related articles for article (PubMed ID: 29076867)
1. Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Basurto E; Joseph RW
Cancer Nurs; 2019; 42(1):E52-E59. PubMed ID: 29076867
[TBL] [Abstract][Full Text] [Related]
2. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
3. Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences.
Fifer SJ; Ho KA; Lybrand S; Axford LJ; Roach S
BMC Cancer; 2020 Jun; 20(1):546. PubMed ID: 32527324
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
5. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
6. Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment.
Weilandt J; Diehl K; Schaarschmidt ML; Kieker F; Sasama B; Pronk M; Ohletz J; Könnecke A; Müller V; Utikal J; Hillen U; Harth W; Peitsch WK
Acta Derm Venereol; 2020 Mar; 100(6):adv00083. PubMed ID: 32057087
[TBL] [Abstract][Full Text] [Related]
7. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.
Livingstone A; Howard K; Menzies AM; Long GV; Stockler MR; Morton RL
Patient; 2023 Sep; 16(5):497-513. PubMed ID: 37351797
[TBL] [Abstract][Full Text] [Related]
8. Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.
Qian Y; Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Hechmati G; Gatta F; Harrelson S; Campbell-Baird C
Patient; 2016 Aug; 9(4):323-33. PubMed ID: 26821359
[TBL] [Abstract][Full Text] [Related]
9. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
[TBL] [Abstract][Full Text] [Related]
10. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for treatment of advanced melanoma: impact of comorbidities.
Weilandt J; Diehl K; Schaarschmidt ML; Kiecker F; Sasama B; Pronk M; Ohletz J; Könnecke A; Müller V; Utikal J; Hillen U; Harth W; Peitsch WK
J Dtsch Dermatol Ges; 2021 Jan; 19(1):58-70. PubMed ID: 33015933
[TBL] [Abstract][Full Text] [Related]
12. Registered nurses' preferences for rural and urban jobs: A discrete choice experiment.
Fields BE; Bell JF; Bigbee JL; Thurston H; Spetz J
Int J Nurs Stud; 2018 Oct; 86():11-19. PubMed ID: 29958138
[TBL] [Abstract][Full Text] [Related]
13. Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies.
Ettinger AB; Carter JA; Rajagopalan K
Epilepsy Behav; 2018 Mar; 80():247-253. PubMed ID: 29433949
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
[TBL] [Abstract][Full Text] [Related]
15. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
[TBL] [Abstract][Full Text] [Related]
16. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
17. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
[TBL] [Abstract][Full Text] [Related]
18. Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?
Veldwijk J; Essers BA; Lambooij MS; Dirksen CD; Smit HA; de Wit GA
Value Health; 2016; 19(2):202-9. PubMed ID: 27021754
[TBL] [Abstract][Full Text] [Related]
19. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
[TBL] [Abstract][Full Text] [Related]
20. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
